MeiraGTx enters collaboration with Hologen AI: $200M upfront, $230M JV funding for AAV-GAD

MeiraGTx Holdings plc

Received $200M upfront cash from Hologen; forming JV Hologen Neuro AI Ltd.
Hologen commits up to $230M additional capital to JV to fund AAV-GAD Parkinson's development.
MeiraGTx retains 30% ownership in JV, leads clinical development and manufacturing.
Hologen takes minority stake in MeiraGTx's manufacturing subsidiary; AI optimization.
Closing expected Q2 2025, subject to UK FDI regulatory approvals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.